In fact, in other types of cancer, such as thyroid cancer, it has already been demonstrated that vitamin C kills thyroid cancer cells by inhibiting MAPK/ERK and PI3K/AKT pathways via a ROS-dependent mechanism, suggesting that pharmaceutical concentration of vitamin C has potential clinical use in thyroid cancer therapy [34]. Here, AKT1 is linked to thyroid cancer.